Boston Scientific (NYSE:BSX) Downgraded by Erste Group Bank to “Hold”

Erste Group Bank downgraded shares of Boston Scientific (NYSE:BSX) from a buy rating to a hold rating in a research note issued to investors on Friday morning, MarketBeat.com reports.

Several other research analysts also recently commented on BSX. Needham & Company LLC restated a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research note on Wednesday. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Leerink Partners upped their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Finally, UBS Group boosted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $120.79.

Boston Scientific Stock Up 1.1%

BSX opened at $97.30 on Friday. Boston Scientific has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a market cap of $144.17 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average of $102.93 and a 200 day moving average of $102.05.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the previous year, the firm posted $0.62 EPS. The business’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts expect that Boston Scientific will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $17,972,457 over the last quarter. 0.50% of the stock is owned by company insiders.

Institutional Trading of Boston Scientific

Several institutional investors have recently added to or reduced their stakes in the business. 1248 Management LLC purchased a new position in shares of Boston Scientific in the first quarter worth about $26,000. FWL Investment Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth approximately $26,000. Y.D. More Investments Ltd bought a new stake in Boston Scientific in the first quarter valued at approximately $27,000. Sound Income Strategies LLC boosted its stake in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Finally, Kilter Group LLC bought a new position in shares of Boston Scientific in the second quarter worth approximately $30,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.